We are live on
!
Find out more
BioCryst Pharmaceuticals
BCRX
BCRX
273 hedge funds and large institutions have $1.66B invested in BioCryst Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 92 increasing their positions, 101 reducing their positions, and 57 closing their positions.
New
Increased
Maintained
Reduced
Closed
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
55% more call options, than puts
Call options by funds: $12M | Put options by funds: $7.76M
12% more capital invested
Capital invested by funds: $1.48B → $1.66B (+$182M)
8.36% more ownership
Funds ownership: 92.5% → 100.86% (+8.4%)
9% less repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 101
5% less funds holding
Funds holding: 286 → 273 (-13)
14% less first-time investments, than exits
New positions opened: 49 | Existing positions closed: 57
Holders
273
Holders Change
-13
Holders Change %
-4.55%
% of All Funds
3.32%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.04%
New
49
Increased
92
Reduced
101
Closed
57
Calls
$12M
Puts
$7.76M
Net Calls
+$4.27M
Net Calls Change
+$2.39M
Top Buyers
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$114M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$52.9M |
| 3 |
PA
Perceptive Advisors
New York
|
+$22.9M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$20.4M |
| 5 |
VPC
Vestal Point Capital
New York
|
+$16.3M |
